See the published version of this preprint at BMC Cancer.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
Research article
Pingping Wu
affiliated cancer hospital of nanjing medical university
Corresponding Author
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Recurrence and metastasis are the shortcomings of the clinical treatment of colon cancer. Finding an efficacy strategy for the treatment of colon cancer is important. In recent years, PLGA has been shown to have potential as a broad therapeutic drug delivery system. this study aimed to design a dual-loaded nanoparticles drug delivery system to overcome the limitations of chemotherapeutic drugs in colon cancer therapy. We developed epidermal growth factor (EGF) functionalized poly (lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) co-loaded with 5-fluorouracil (5Fu) and perfluorocarbon (PFC) ([email protected]/PFC) for target therapy of colon cancer. [email protected] /PFC NPs were estimated to have an average size of 200 nm with a 5Fu-loading efficiency of 7.29%. In vitro release profile exhibited a pH-responsive release. CCK-8, Hoechst33342 staining and flow cytometry assays were performed to investigate the functions of [email protected]/PFC NPs in SW620 cells. Targeted [email protected]/PFC NPs also exhibited higher cellular uptake than non-targeted NPs in colon cancer cells. [email protected]/PFC NPs were found to have the best efficiency on cell viability suppression and apoptosis induction in SW620 cells. In xenograft mice, [email protected]/PFC NPs had the best suppressive effects on tumor growth compared with 5Fu, [email protected] and [email protected]/PFC NPs. The results of histopathological analysis further indicated that EGF-targeted NPs were the most efficient on tumor growth inhibition. Mechanically, the data demonstrated the improved therapeutic outcomes were owing to the fact that PFC could relieve tumor hypoxia via transporting oxygen to the tumor. We creatively constructed a biocompatible nanodrug delivery system and functionalized nanoparticles may provide new potential for selective delivery of chemotherapy drugs to cancers.
Keywords
PLGA nanoparticles, 5-fluorouracil, perfluorocarbon, EGF, hypoxia, colon cancer
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
This is a list of supplementary files associated with this preprint. Click to download.
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at BMC Cancer.
No community comments so far
Editorial decision: Accept
On 27 Mar, 2020
Editor assigned
On 26 Mar, 2020
Submission checks complete
On 25 Mar, 2020
Editor invited
On 25 Mar, 2020
No comments provided
Editorial decision: Minor revision
On 23 Mar, 2020
Review #2 received
Received 18 Mar, 2020
Review #1 received
Received 14 Mar, 2020
Reviewer #2 agreed
On 03 Mar, 2020
Editor assigned
On 26 Feb, 2020
Reviewers invited
Invitations sent on 26 Feb, 2020
Reviewer #1 agreed
On 26 Feb, 2020
Submission checks complete
On 25 Feb, 2020
Editor invited
On 25 Feb, 2020
No comments provided
Editorial decision: Minor revision
On 11 Jan, 2020
Review #1 received
Received 31 Dec, 2019
Reviewer #2 agreed
On 20 Dec, 2019
Review #2 received
Received 20 Dec, 2019
Reviewers invited
Invitations sent on 16 Dec, 2019
Reviewer #1 agreed
On 16 Dec, 2019
Editor assigned
On 13 Dec, 2019
Submission checks complete
On 12 Dec, 2019
Editor invited
On 12 Dec, 2019
Version 1
Posted 20 Nov, 2019
No comments provided
Editorial decision: Minor revision
On 09 Dec, 2019
Review #4 received
Received 06 Dec, 2019
Review #2 received
Received 30 Nov, 2019
Review #1 received
Received 25 Nov, 2019
Reviewer #5 agreed
On 23 Nov, 2019
Reviewer #4 agreed
On 22 Nov, 2019
Review #3 received
Received 22 Nov, 2019
Reviewer #3 agreed
On 22 Nov, 2019
Reviewer #2 agreed
On 19 Nov, 2019
Reviewer #1 agreed
On 15 Nov, 2019
Submission checks complete
On 11 Nov, 2019
Editor invited
On 11 Nov, 2019
Editor assigned
On 11 Nov, 2019
Reviewers invited
Invitations sent on 11 Nov, 2019
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Oncology
Learn more about our company.
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
See the published version of this preprint at BMC Cancer.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research article
Pingping Wu
affiliated cancer hospital of nanjing medical university
Corresponding Author
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at BMC Cancer.
No community comments so far
Editorial decision: Accept
On 27 Mar, 2020
Editor assigned
On 26 Mar, 2020
Submission checks complete
On 25 Mar, 2020
Editor invited
On 25 Mar, 2020
No comments provided
Editorial decision: Minor revision
On 23 Mar, 2020
Review #2 received
Received 18 Mar, 2020
Review #1 received
Received 14 Mar, 2020
Reviewer #2 agreed
On 03 Mar, 2020
Editor assigned
On 26 Feb, 2020
Reviewers invited
Invitations sent on 26 Feb, 2020
Reviewer #1 agreed
On 26 Feb, 2020
Submission checks complete
On 25 Feb, 2020
Editor invited
On 25 Feb, 2020
No comments provided
Editorial decision: Minor revision
On 11 Jan, 2020
Review #1 received
Received 31 Dec, 2019
Reviewer #2 agreed
On 20 Dec, 2019
Review #2 received
Received 20 Dec, 2019
Reviewers invited
Invitations sent on 16 Dec, 2019
Reviewer #1 agreed
On 16 Dec, 2019
Editor assigned
On 13 Dec, 2019
Submission checks complete
On 12 Dec, 2019
Editor invited
On 12 Dec, 2019
Version 1
Posted 20 Nov, 2019
No comments provided
Editorial decision: Minor revision
On 09 Dec, 2019
Review #4 received
Received 06 Dec, 2019
Review #2 received
Received 30 Nov, 2019
Review #1 received
Received 25 Nov, 2019
Reviewer #5 agreed
On 23 Nov, 2019
Reviewer #4 agreed
On 22 Nov, 2019
Review #3 received
Received 22 Nov, 2019
Reviewer #3 agreed
On 22 Nov, 2019
Reviewer #2 agreed
On 19 Nov, 2019
Reviewer #1 agreed
On 15 Nov, 2019
Submission checks complete
On 11 Nov, 2019
Editor invited
On 11 Nov, 2019
Editor assigned
On 11 Nov, 2019
Reviewers invited
Invitations sent on 11 Nov, 2019
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Oncology
License:
This work is licensed under a CC BY 4.0 License. Read Full License
View the published article at BMC Cancer.
Recurrence and metastasis are the shortcomings of the clinical treatment of colon cancer. Finding an efficacy strategy for the treatment of colon cancer is important. In recent years, PLGA has been shown to have potential as a broad therapeutic drug delivery system. this study aimed to design a dual-loaded nanoparticles drug delivery system to overcome the limitations of chemotherapeutic drugs in colon cancer therapy. We developed epidermal growth factor (EGF) functionalized poly (lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) co-loaded with 5-fluorouracil (5Fu) and perfluorocarbon (PFC) ([email protected]/PFC) for target therapy of colon cancer. [email protected] /PFC NPs were estimated to have an average size of 200 nm with a 5Fu-loading efficiency of 7.29%. In vitro release profile exhibited a pH-responsive release. CCK-8, Hoechst33342 staining and flow cytometry assays were performed to investigate the functions of [email protected]/PFC NPs in SW620 cells. Targeted [email protected]/PFC NPs also exhibited higher cellular uptake than non-targeted NPs in colon cancer cells. [email protected]/PFC NPs were found to have the best efficiency on cell viability suppression and apoptosis induction in SW620 cells. In xenograft mice, [email protected]/PFC NPs had the best suppressive effects on tumor growth compared with 5Fu, [email protected] and [email protected]/PFC NPs. The results of histopathological analysis further indicated that EGF-targeted NPs were the most efficient on tumor growth inhibition. Mechanically, the data demonstrated the improved therapeutic outcomes were owing to the fact that PFC could relieve tumor hypoxia via transporting oxygen to the tumor. We creatively constructed a biocompatible nanodrug delivery system and functionalized nanoparticles may provide new potential for selective delivery of chemotherapy drugs to cancers.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
This is a list of supplementary files associated with this preprint. Click to download.
Loading...